CoImmune is a privately held, clinical stage immuno-oncology company that will redefine cancer treatment using best-in-class cellular immunotherapies. Our allogeneic CAR-CIK technology platform for liquid and solid tumors is a variation on CAR-T therapy that promises enhanced efficacy with greatly reduced toxicity. Our autologous RNA-loaded dendritic cell technology for solid tumors uses amplified total tumor mRNA to program highly engineered dendritic cells to generate immune responses against neoantigens without the need to identify them.
CoImmune Inc. is a US company based in Durham North Carolina that was founded in 2019 based on its expertise in the development and manufacture of cell-based therapeutics to treat unmet medical needs including cancer, autoimmune and inflammatory diseases. CoImmune has a 20,000 sq. ft. cGMP manufacturing facility capable of supporting clinical studies from Phase 1 through Phase 3. The company is preparing to initiate its first Phase 2 clinical trial using a strategic combination of immuno-oncology therapeutics.
“All of us at CoImmune are very excited by the work we are doing with our colleagues in Italy. We are planning additional clinical trials to be conducted in the United States and Italy targeting B-ALL, chronic lymphocytic leukemia, non-Hodgkin’s lymphoma and acute myelogenous leukemia”
CoImmune, Inc., a clinical stage immuno-oncology company working to redefine cancer treatment using best-in-class cellular immunotherapies, today announced the appointment of Dr. Ed Baracchini as chairman of the Company’s board of directors. “As a member of the CoImmune board of directors, Dr. Baracchini has provided strong counsel and guidance on many important issues in corporate …
CoImmune, Inc., a clinical stage immuno-oncology company working to redefine cancer treatment using best-in-class cellular immunotherapies, today announced a license and collaboration agreement with Memorial Sloan Kettering Cancer Center (MSK) to accelerate the adaptation of CoImmune’s proprietary allogeneic CAR-CIK technology platform to treat solid tumors. Under the terms of the agreement, CoImmune is acquiring rights …
